In our current study, we showed that targeting of intratumoral Tregs with ASO FOXP3 was accompanied by significant reduction in expression of exhaustion molecules on the tumor T cells, in vivo in tumor models and in vitro in human primary tumor samples. This evidence concerns the gene FOXP3 and neoplasm.